Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, March 1, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Yanan Zhu Initiated (TSHA) at Buy and Held Target at $25 on, Mar 1st, 2022
Yanan Zhu of Wells Fargo, Initiated "Taysha Gene Therapies, Inc." (TSHA) at Buy and Held Target at $25 on, Mar 1st, 2022.
Yanan has made no other calls on TSHA in the last 4 months.
There are 2 other peers that have a rating on TSHA. Out of the 2 peers that are also analyzing TSHA, 0 agree with Yanan's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Yanan
- Debjit Chattopadhyay of "Guggenheim" Initiated at Strong Buy and Held Target at $28 on, Thursday, December 16th, 2021
- Silvan Tuerkcan of "JMP Securities" Maintained at Buy with Decreased Target to $38 on, Thursday, November 11th, 2021
